<p>OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 在最近向美国证券交易委员会提交的 13F 表格中披露，第二季度其在 Praxis Precision Medicines, Inc. (NASDAQ:PRAX - 免费报告) 的持股减少了 18.3%。该基金在季度内出售了 4,901 股后，持有该公司 21,892 股股票。OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 在最近的报告期末持有约 0.10% 的 Praxis Precision Medicines，价值 921,000 美元。</p>
<p>其他一些机构投资者最近也增加或减少了在 PRAX 的持股。HighVista Strategies LLC 在第二季度将其在 Praxis Precision Medicines 的持股增加了 71.3%。HighVista Strategies LLC 目前持有 67,288 股该公司的股票，价值 2,829,000 美元，此前在上个季度又购买了 28,002 股。Stempoint Capital LP 在第二季度购买了 Praxis Precision Medicines 的新股份，价值 1,356,000 美元。B Group Inc. 在第二季度将其在 Praxis Precision Medicines 的持股增加了 84.2%。B Group Inc. 目前持有 35,000 股该公司的股票，价值 1,472,000 美元，此前在该期间又收购了 16,000 股。Vivo Capital LLC 在第二季度收购了 Praxis Precision Medicines 的新股份，估计价值约为 7,048,000 美元。最后，Maven Securities LTD 在第二季度购买了 Praxis Precision Medicines 的新股份，估计价值约为 210,000 美元。对冲基金和其他机构投资者持有该公司 67.84% 的股票。</p>
<h2>Praxis Precision Medicines 的内部交易</h2>
<p>在相关消息中，首席法律顾问 Alex Nemiroff 于 11 月 20 日星期四出售了 25,130 股该公司的股票。股票以平均价格 193.09 美元出售，总交易额为 4,852,351.70 美元。交易完成后，首席法律顾问直接持有该公司 20,832 股股票，价值 4,022,450.88 美元。此交易代表其持股减少了 54.68%。该出售在向美国证券交易委员会的法律文件中披露，相关文件可通过此链接获取。此外，内部人士 Lauren Mastrocola 于 11 月 20 日星期四出售了 13,600 股该公司的股票。股票以平均价格 192.08 美元出售，总交易额为 2,612,288.00 美元。出售后，内部人士持有该公司 10,442 股股票，价值 2,005,699.36 美元。此交易代表其持股减少了 56.57%。该出售的披露信息可在美国证券交易委员会的文件中找到。公司内部人士持有该公司 2.70% 的股票。</p>
<h2>分析师评级的升级和降级</h2>
<p>多位股票分析师对该股票发表了评论。Guggenheim 在周二的研究报告中重申了对 Praxis Precision Medicines 的 &#34;买入&#34; 评级，并将目标价格从 540.00 美元上调至 760.00 美元。Truist Financial 在周一将 Praxis Precision Medicines 的目标价格从 360.00 美元提高到 500.00 美元，并给予该公司 &#34;买入&#34; 评级。Weiss Ratings 在周一的研究报告中重申了对 Praxis Precision Medicines 的 &#34;卖出 (e+)&#34; 评级。HC Wainwright 在 12 月 5 日星期五重申了 &#34;买入&#34; 评级，并将目标价格从 258.00 美元上调至 340.00 美元。最后，Chardan Capital 在 11 月 19 日星期三将 Praxis Precision Medicines 的评级上调至 &#34;强力买入&#34;。两位研究分析师对该股票给予了强力买入评级，十三位给予了买入评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 &#34;适度买入&#34;，共识目标价格为 333.00 美元。</p>
<p><strong>阅读我们关于 Praxis Precision Medicines 的最新股票报告</strong></p>
<h2>Praxis Precision Medicines 股票上涨 2.2%</h2>
<p>NASDAQ PRAX 的股票在周五开盘时为 267.28 美元。该公司的市值为 66.8 亿美元，市盈率为 -20.72，贝塔值为 2.95。Praxis Precision Medicines, Inc. 的 52 周低点为 26.70 美元，52 周高点为 278.44 美元。该公司的 50 日移动平均线为 167.50 美元，200 日移动平均线为 88.71 美元。</p>
<p>Praxis Precision Medicines (NASDAQ:PRAX - 获取免费报告) 最近于 11 月 5 日星期三发布了季度财报。该公司报告季度每股收益为 ($3.36)，超出市场共识预期的 ($3.45) 0.09 美元。分析师预计 Praxis Precision Medicines, Inc. 在当前财政年度将发布 -10.22 的每股收益。</p>
<h2>Praxis Precision Medicines 公司简介</h2>
<p>(免费报告)</p>
<p>Praxis Precision Medicines, Inc. 是一家临床阶段的生物制药公司，专注于开发针对中枢神经系统疾病的治疗，这些疾病的特征是神经兴奋 - 抑制失衡。该公司正在开发 ulixacaltamide，这是一种 T 型钙通道的小分子抑制剂，目前正在进行 III 期临床试验，治疗原发性震颤；PRAX-562 用于治疗患有发育性和癫痫性脑病 (DEE) 的儿童患者；以及 PRAX-628 用于治疗局灶性癫痫。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而非 Praxis Precision Medicines</li>
<li>专家股票交易心理学技巧</li>
<li>2026 年应避免的三只最近被降级的股票</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>芯片热潮回归：三只有望大幅上涨的股票</li>
<li>投资建筑类股票</li>
<li>甲骨文股票遭重创：为何其 AI 管道可能推动 2026 年的反弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Praxis Precision Medicines 吗？</h2>
<p>在考虑投资 Praxis Precision Medicines 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而 Praxis Precision Medicines 并不在名单上。</p>
<p>虽然 Praxis Precision Medicines 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRAX

<p>OCONNOR，瑞银资产管理的一个部门，在第二季度减少了对 Praxis Precision Medicines 的持股 18.3%。其他机构投资者也调整了他们的持仓，其中一些增加了他们的股份。内部交易包括公司高管的大量股票出售。分析师的评级各不相同，普遍共识为 “适度买入”，目标价格为 333 美元。Praxis 的股票上涨了 2.2%，市值为 66.8 亿美元</p>

<p>OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 18.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 21,892 shares of the company's stock after selling 4,901 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.10% of Praxis Precision Medicines worth $921,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 在最近向美国证券交易委员会提交的 13F 表格中披露，第二季度其在 Praxis Precision Medicines, Inc. (NASDAQ:PRAX - 免费报告) 的持股减少了 18.3%。该基金在季度内出售了 4,901 股后，持有该公司 21,892 股股票。OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 在最近的报告期末持有约 0.10% 的 Praxis Precision Medicines，价值 921,000 美元。</p>
</div><p>A number of other institutional investors have also recently added to or reduced their stakes in PRAX. HighVista Strategies LLC boosted its stake in Praxis Precision Medicines by 71.3% during the second quarter. HighVista Strategies LLC now owns 67,288 shares of the company's stock worth $2,829,000 after buying an additional 28,002 shares during the last quarter. Stempoint Capital LP purchased a new position in shares of Praxis Precision Medicines during the 2nd quarter worth $1,356,000. B Group Inc. raised its holdings in shares of Praxis Precision Medicines by 84.2% during the 2nd quarter. B Group Inc. now owns 35,000 shares of the company's stock worth $1,472,000 after acquiring an additional 16,000 shares during the period. Vivo Capital LLC acquired a new position in shares of Praxis Precision Medicines during the 2nd quarter valued at about $7,048,000. Finally, Maven Securities LTD purchased a new stake in shares of Praxis Precision Medicines in the second quarter valued at about $210,000. Hedge funds and other institutional investors own 67.84% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也增加或减少了在 PRAX 的持股。HighVista Strategies LLC 在第二季度将其在 Praxis Precision Medicines 的持股增加了 71.3%。HighVista Strategies LLC 目前持有 67,288 股该公司的股票，价值 2,829,000 美元，此前在上个季度又购买了 28,002 股。Stempoint Capital LP 在第二季度购买了 Praxis Precision Medicines 的新股份，价值 1,356,000 美元。B Group Inc. 在第二季度将其在 Praxis Precision Medicines 的持股增加了 84.2%。B Group Inc. 目前持有 35,000 股该公司的股票，价值 1,472,000 美元，此前在该期间又收购了 16,000 股。Vivo Capital LLC 在第二季度收购了 Praxis Precision Medicines 的新股份，估计价值约为 7,048,000 美元。最后，Maven Securities LTD 在第二季度购买了 Praxis Precision Medicines 的新股份，估计价值约为 210,000 美元。对冲基金和其他机构投资者持有该公司 67.84% 的股票。</p>
</div><h2>Insider Transactions at Praxis Precision Medicines</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 的内部交易</h2>
</div><p>In related news, General Counsel Alex Nemiroff sold 25,130 shares of the firm's stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $193.09, for a total transaction of $4,852,351.70. Following the completion of the transaction, the general counsel directly owned 20,832 shares in the company, valued at $4,022,450.88. This trade represents a 54.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Lauren Mastrocola sold 13,600 shares of the business's stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $192.08, for a total transaction of $2,612,288.00. Following the sale, the insider owned 10,442 shares in the company, valued at $2,005,699.36. This trade represents a 56.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 2.70% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席法律顾问 Alex Nemiroff 于 11 月 20 日星期四出售了 25,130 股该公司的股票。股票以平均价格 193.09 美元出售，总交易额为 4,852,351.70 美元。交易完成后，首席法律顾问直接持有该公司 20,832 股股票，价值 4,022,450.88 美元。此交易代表其持股减少了 54.68%。该出售在向美国证券交易委员会的法律文件中披露，相关文件可通过此链接获取。此外，内部人士 Lauren Mastrocola 于 11 月 20 日星期四出售了 13,600 股该公司的股票。股票以平均价格 192.08 美元出售，总交易额为 2,612,288.00 美元。出售后，内部人士持有该公司 10,442 股股票，价值 2,005,699.36 美元。此交易代表其持股减少了 56.57%。该出售的披露信息可在美国证券交易委员会的文件中找到。公司内部人士持有该公司 2.70% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级的升级和降级</h2>
</div><p>A number of equities analysts have commented on the stock. Guggenheim reaffirmed a &#34;buy&#34; rating and set a $760.00 target price (up from $540.00) on shares of Praxis Precision Medicines in a research note on Tuesday. Truist Financial increased their price target on shares of Praxis Precision Medicines from $360.00 to $500.00 and gave the company a &#34;buy&#34; rating in a research note on Monday. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Praxis Precision Medicines in a research report on Monday. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $340.00 price objective (up from $258.00) on shares of Praxis Precision Medicines in a report on Friday, December 5th. Finally, Chardan Capital upgraded Praxis Precision Medicines to a &#34;strong-buy&#34; rating in a research report on Wednesday, November 19th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $333.00.</p>
<div class="lb-trans"><p>多位股票分析师对该股票发表了评论。Guggenheim 在周二的研究报告中重申了对 Praxis Precision Medicines 的 &#34;买入&#34; 评级，并将目标价格从 540.00 美元上调至 760.00 美元。Truist Financial 在周一将 Praxis Precision Medicines 的目标价格从 360.00 美元提高到 500.00 美元，并给予该公司 &#34;买入&#34; 评级。Weiss Ratings 在周一的研究报告中重申了对 Praxis Precision Medicines 的 &#34;卖出 (e+)&#34; 评级。HC Wainwright 在 12 月 5 日星期五重申了 &#34;买入&#34; 评级，并将目标价格从 258.00 美元上调至 340.00 美元。最后，Chardan Capital 在 11 月 19 日星期三将 Praxis Precision Medicines 的评级上调至 &#34;强力买入&#34;。两位研究分析师对该股票给予了强力买入评级，十三位给予了买入评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 &#34;适度买入&#34;，共识目标价格为 333.00 美元。</p>
</div><p><strong>Read Our Latest Stock Report on Praxis Precision Medicines</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Praxis Precision Medicines 的最新股票报告</strong></p>
</div><h2>Praxis Precision Medicines Stock Up 2.2%</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 股票上涨 2.2%</h2>
</div><p>Shares of NASDAQ PRAX opened at $267.28 on Friday. The firm has a market cap of $6.68 billion, a price-to-earnings ratio of -20.72 and a beta of 2.95. Praxis Precision Medicines, Inc. has a 52-week low of $26.70 and a 52-week high of $278.44. The business's 50 day moving average is $167.50 and its two-hundred day moving average is $88.71.</p>
<div class="lb-trans"><p>NASDAQ PRAX 的股票在周五开盘时为 267.28 美元。该公司的市值为 66.8 亿美元，市盈率为 -20.72，贝塔值为 2.95。Praxis Precision Medicines, Inc. 的 52 周低点为 26.70 美元，52 周高点为 278.44 美元。该公司的 50 日移动平均线为 167.50 美元，200 日移动平均线为 88.71 美元。</p>
</div><p>Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($3.36) EPS for the quarter, topping the consensus estimate of ($3.45) by $0.09. Analysts anticipate that Praxis Precision Medicines, Inc. will post -10.22 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Praxis Precision Medicines (NASDAQ:PRAX - 获取免费报告) 最近于 11 月 5 日星期三发布了季度财报。该公司报告季度每股收益为 ($3.36)，超出市场共识预期的 ($3.45) 0.09 美元。分析师预计 Praxis Precision Medicines, Inc. 在当前财政年度将发布 -10.22 的每股收益。</p>
</div><h2>Praxis Precision Medicines Company Profile</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.</p>
<div class="lb-trans"><p>Praxis Precision Medicines, Inc. 是一家临床阶段的生物制药公司，专注于开发针对中枢神经系统疾病的治疗，这些疾病的特征是神经兴奋 - 抑制失衡。该公司正在开发 ulixacaltamide，这是一种 T 型钙通道的小分子抑制剂，目前正在进行 III 期临床试验，治疗原发性震颤；PRAX-562 用于治疗患有发育性和癫痫性脑病 (DEE) 的儿童患者；以及 PRAX-628 用于治疗局灶性癫痫。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Praxis Precision Medicines</li>
<li>Expert Stock Trading Psychology Tips</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>Investing in Construction Stocks</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Praxis Precision Medicines</li>
<li>专家股票交易心理学技巧</li>
<li>2026 年应避免的三只最近被降级的股票</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>芯片热潮回归：三只有望大幅上涨的股票</li>
<li>投资建筑类股票</li>
<li>甲骨文股票遭重创：为何其 AI 管道可能推动 2026 年的反弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PRAX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Praxis Precision Medicines Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Praxis Precision Medicines 吗？</h2>
</div><p>Before you consider Praxis Precision Medicines, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Praxis Precision Medicines 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而 Praxis Precision Medicines 并不在名单上。</p>
</div><p>While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Praxis Precision Medicines 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

OCONNOR 是瑞银资产管理美洲有限责任公司的一家独立业务部门，该部门减少了在 Praxis Precision Medicines, Inc. $PRAX 的股票持仓